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Background and Aims: Changes in gut serotonin (5-HT) content have been described
in Inflammatory Bowel Disease (IBD) and in different experimental models of colitis:
the critical role of this monoamine in the pathogenesis of chronic gastrointestinal
inflammation is gradually emerging. Aim of the present study was to evaluate the
contribution of endogenous 5-HT through the activation of its specific receptor subtypes
to the local and systemic inflammatory responses in an experimental model of IBD.
Materials and Methods: Colitis was induced by intrarectal 2,4,6-TriNitroBenzene
Sulfonic acid in mice subacutely treated with selective antagonists of 5-HT1A
(WAY100135), 5-HT2A (Ketanserin), 5-HT3 (Ondansetron), 5-HT4 (GR125487), 5-HT7
(SB269970) receptors and with 5-HT1A agonist 8-Hydroxy-2-(di-n-propylamino)tetralin.
Results: Blockade of 5-HT1A receptors worsened TNBS-induced local and systemic
neutrophil recruitment while 5-HT1A agonist delayed and mitigated the severity of colitis,
counteracting the increase in colonic 5-HT content. On the contrary, blockade of
5-HT2A receptors improved global health conditions, reduced colonic morphological
alterations, down-regulated neutrophil recruitment, inflammatory cytokines levels and
colonic apoptosis. Antagonism of 5-HT3, 5-HT4, and 5-HT7 receptor sites did not
remarkably affect the progression and outcome of the pathology or only slightly
improved it.
Conclusion: The prevailing deleterious contribution given by endogenous 5-HT to
inflammation in TNBS-induced colitis is seemingly mediated by 5-HT2A and, to a lesser
extent, by 5-HT4 receptors and coexists with the weak beneficial effect elicited by 5-
HT1A stimulation. These findings suggest how only a selective interference with 5-HT
pro-inflammatory actions may represent an additional potential therapeutic option for
intestinal inflammatory disorders.
Keywords: intestine, inflammation, 5-HT2A receptor, 5-HT1A receptor, apoptosis
Abbreviations: 5-HT, Serotonin; 8-OH-DPAT, 8-Hydroxy-2-(di-n-propylamino)tetralin; C, Control; CD, Crohn’s Disease;
DAI, Disease Activity Index; EC, Enterochromaffin; G, GR125487; GI, Gastrointestinal; HSP70, Heat Shock Protein-70; IBD,
Inflammatory Bowel Disease; IBS, Irritable Bowel Sindrome; IFN, Interferon; IL, Interleukin; K, Ketanserin; MS, Macroscopic
Score; MPO, Myeloperoxidase; N, Normal; NO, Nitric oxide; O, Ondansetron; S, SB269970; SERT, Serotonin Reuptake
Transporter; SP, Substance P; TNBS, 2,4,6-TriNitroBenzene Sulfonic acid; TNF, Tumor necrosis factor; Tph1, Tryptophan
hydroxylase 1; UC, Ulcerative Colitis; W, WAY100135.
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INTRODUCTION
Serotonin (or 5-Hydroxytryptamine, 5-HT) is a well-known
mediator both in the brain and in the periphery. In the
periphery, 5-HT plays a pivotal role as paracrine mediator and
neurotransmitter; in particular, in the GI tract, where most
of the monoamine resides, 5-HT is stored in EC cells and
serotonergic neurons of the myenteric plexus and is released
for the physiological regulation of gut motility, secretion and
perception (De Ponti, 2004). Abnormalities in serotonergic
signaling have been reported in a number of functional and
inflammatory GI disorders, both clinical and experimental, like
IBS (Spiller, 2008), mesenteric ischemia-reperfusion (Teramoto
et al., 1998; Bertoni et al., 2007; Bertoni et al., 2014), celiac
disease (Coleman et al., 2006) and IBD (Belai et al., 1997). IBD,
including CD and UC, is a chronic inflammatory disorder with
relapsing and remitting course, one of the most serious diseases
affecting human bowel: its incidence is increasing worldwide
and, up to now, remains incurable. Enhanced or, alternatively,
lowered EC cell numbers and 5-HT content have been reported
in association with both CD and UC (El-Salhy et al., 1997;
Magro et al., 2002). In different experimental models of colitis
increased 5-HT content has been observed (Oshima et al., 1999;
Linden et al., 2003). Accordingly, mice lacking 5-HT re-uptake
transporter (SERT) exhibited exacerbation of chemically and
genetically induced colitis (Bischoff et al., 2009); conversely, a
lower damage was reported in mice with reduced availability of
gut 5-HT, through genetic deletion or pharmacological inhibition
of Tph1 (Ghia et al., 2009; Margolis et al., 2014; Kim et al.,
2015).
Decisive to its involvement in the patho-physiology of
a chronic inflammatory condition like IBD, triggered by a
dysregulated immune response (Abraham and Cho, 2009), is the
influence of 5-HT both on GI and on immune system functions.
Indeed, 5-HT exerts a wide range of effects in the gut through the
interaction with multiple receptor subtypes present on smooth
muscle, enteric neurons and enterocytes but also on innate and
adaptive immune cells, like monocytes, macrophages, dendritic
cells, B and T lymphocytes (Manocha and Khan, 2012; Arreola
et al., 2015). Despite this wealth of information, the role played
by the distinct 5-HT receptor subtypes in IBD pathogenesis and
progression has yet to be unraveled.
Aim of the present work was therefore to evaluate the
contribution given by endogenous 5-HT through the activation
of specific receptor subtypes, shown to be expressed in the
GI tract, to the local and systemic inflammatory responses
induced in an acute murine model of CD. Accordingly, we
first verified the increase in colonic 5-HT content in TNBS-
induced colitis; second, we evaluated the effects produced
by the repeated administration of selective antagonists
of 5-HT1A (WAY100135), 5-HT2A (Ketanserin), 5-HT3
(Ondansetron), 5-HT4 (GR125487), and 5-HT7 (SB269970)
receptors in the same experimental model. In order to gain
further insight into the beneficial action shown by Ketanserin,
we tested its ability to prevent colonic apoptosis, typically
increased in clinical and experimental colitis and regarded
as contributing factor in IBD pathogenesis (Günther et al.,
2013), and to promote epithelial cell protection via the stress-
inducible HSP70, whose expression has been reported to
be down-regulated in IBD (Hu et al., 2007). Finally, given
the massive leukocyte recruitment triggered by blockade
of 5-HT1A receptors in colitic animals, we investigated the
potential protective activity afforded by their stimulation
through the administration of the selective 5-HT1A agonist
8-OH-DPAT.
MATERIALS AND METHODS
Animals
Swiss CD1 female mice, 6–10 weeks old (Charles River
Laboratories, Calco, Italy) weighing 25–30 g, were housed five
per cage, under standard conditions (12:12 h light–dark cycle,
water and food ad libitum, 22–24◦C). All the experiments were
performed in accordance with Guiding Principles in the Care
and Use of Animals (DL116/92) and were authorized by the local
Animal Care Committee “Organismo preposto al benessere degli
animali” and by Italian Ministry of Health.
Induction of Colitis and Experimental
Protocol
To induce colitis, mice were lightly anesthetized with diethyl
ether and a 10-cm long PE-50 tubing attached to a tuberculin
syringe was inserted 2 cm into the colon; 50 µl of a 10%
(w/v) TNBS solution in 50% ethanol was administered to mice,
maintained in a vertical head-down position for 1 min to avoid
leakage of the haptenating agent. Normal (N) animals, receiving
50 µl saline (0.9% NaCl) intrarectally, were included in the study
as reference physiological group.
Mice were randomly assigned to the N group (16 animals),
receiving subcutaneously saline (10 ml/kg), or to the following
experimental groups of colitic animals: saline (C, 10 ml/kg; 16
animals), WAY100135 (W, 5 mg/kg; 12 animals), Ketanserin
(K, 5 mg/kg; 12 animals), Ondansetron (O, 10 mg/kg; 12
animals), GR125487 (G, 10 mg/kg; 12 animals), SB269970
(S, 10 mg/kg; 12 animals) and 8-OH-DPAT (OH, 1 mg/kg;
12 animals). The drugs, subcutaneously administered at doses
chosen according to our preliminary experiments (data not
shown) as effective and not toxic, were repeated twice daily,
starting 1 h after TNBS instillation. Animals were daily weighed
and wellness status was assessed by unaware observers. Mice
were euthanized 3 days after TNBS administration by CO2
inhalation, and organs (colon, liver, lungs) and blood samples
were collected for macroscopic, microscopic, and biochemical
analyses. In particular, for colon assays, each group of animals was
randomly subdivided in three subgroups: colons excised from
each subset was reserved either for histological analysis, for MPO
activity determination or for cytokines assays. In N, C, W, K,
and OH subsets randomly assigned to cytokines determination,
colons were longitudinally sectioned in two halves, each one
being reserved for cytokines determination or, respectively,
for 5-HT and SP levels quantification (N, C, W, and OH
subgroups) or for Caspase-3 and HSP70 assays (N, C and K
subgroups).
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Evaluation of Inflammation
Disease Activity Index
Disease activity index is an evaluation of the pathology severity,
based on the daily assignment of a score according to Cooper’s
modified method (Cooper et al., 1993), on the basis of body
weight loss, stool consistency, and rectal bleeding. The scores
were quantified as follows: stool consistency: 0 (normal), 1 (soft),
2 (liquid); body weight loss: 0 (<5%), 1 (5–10%), 2 (10–15%), 3
(15–20%), 4 (20–25%), 5 (>25%) and rectal bleeding: 0 (absent),
1 (present). Mice were scored blindly by two investigators.
Macroscopic Score (MS)
After the euthanasia, the colon was removed and opened along
the mesenteric line, gently flushed with saline solution and
immediately evaluated for the presence of colonic inflammation.
MS was quantified by a blinded investigator, according to
previously published criteria (Wallace et al., 1989; Khan et al.,
2002), as the sum of scores (max= 12) attributed to the presence
of points of stenosis and hypertrophic zones (0, absent; 1, 1
stenosis; 2, 2 stenoses; 3, more than 2 stenoses), mucus (0, absent;
1, present), adhesions (0, absent; 1, 1 adhesion between colon
and other intra-abdominal organs; 2, 2 adhesions; 3, more than
2 adhesions), intraluminal hemorrhage (0, absent; 1, present),
erythema (0, absent; 1, area < 1 cm2; 2, area > 1 cm2), ulceration
and necrosis zones (0, absent; 1, area < 1 cm2; 2, area > 1 cm2).
Colon Length and Thickness
To evaluate muscular contraction and deposition of amorphous
material induced by massive inflammation, the length of colon,
and cecum and their weight were measured, while weight/length
ratio was calculated to estimate colon thickness (Bischoff et al.,
2009).
Colonic and Hepatic Edema
Colon and liver edemas were measured according to Moore–
Olufemi modified method (Moore-Olufemi et al., 2005). After
euthanasia, organs were rinsed with saline solution, gently milked
dry, and 1 cm long colon segments and a portion of liver were cut
and weighed immediately (wet weight, WW). Tissues were then
allowed to dry for 72 h at room temperature. Dry weights (DW)
were measured and used to determine tissue fluid content from
the following wet to dry ratio: (WW–DW)/DW.
Colonic and Pulmonary MPO Activity Assay
Myeloperoxidase activity, an indicator of tissue neutrophil
accumulation, was determined according to Krawisz’s modified
method (Krawisz et al., 1984). After being weighed, each
colonic and lung sample was homogenized in ice-cold potassium
phosphate buffer (100 mM, pH 7.4) containing aprotinin 1 µg/ml
(1:10, v/v) and centrifuged for 20 min at 12500 RCF at
4◦C. Pellets were re-homogenized in five volumes of ice-cold
potassium phosphate buffer (50 mM, pH 6) containing 0.5%
hexadecylthrimethyl-ammoniumbromide and aprotinin 1 µg
ml−1. The samples were subjected to three cycles of freezing
and thawing, and then centrifuged for 30 min at 15500 RCF
at 4◦C. 100 microliter of the supernatant was then allowed to
react with 900 µl of a buffer solution containing o-dianisidine
(0.167 mg ml−1) and 0.0005% H2O2. Each assay was performed
in duplicate and the rate of change in absorbance was measured
spectrophotometrically at 470 nm (Jenway, mod. 6300, Dunmow,
Essex, England). The sensitivity of the assay was 10 mU/ml, 1
unit of MPO being defined as the quantity of enzyme degrading
1 µmol of peroxide per minute at 25◦C. Data were normalized
with edema values and expressed as U/g of dry weight tissue.
Colonic Cytokines Levels
After euthanasia, colon segments were homogenized for 1 min
in 700 µl of tissue lysis buffer containing 20 mM Tris, 150 mM
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM
EDTA and 0.1% SDS (pH 7.5) and protease inhibitors cocktail
(pepstatin, aprotinin, and leupeptin 1 µg ml−1). Samples were
then centrifuged for 20 min at 16500 RCF at 4◦C and the
supernatant was collected. Total protein concentration was
quantified using Pierce BCA protein assay kit (ThermoFisher
Scientific Inc., MA, USA) and each sample diluted to 5 mg/ml.
IL-1β, TNFα, IFNγ, and IL-10 colonic concentrations were then
determined in duplicate in 100 µl samples, using commercially
available ELISA kits (PRODOTTI GIANNI S.p.A., Milano, Italy),
according to the manufacturer’s protocol, with assays sensitivity,
respectively, of 1 pg/ml (IL-1β), 8 pg/ml (TNFα), 10 pg/ml
(IFNγ), and 30 pg/ml (IL-10). Results were expressed as pg/mg
protein.
Plasmatic Cytokines Levels
Blood was collected by cardiac puncture after CO2 euthanasia,
using heparin as anticoagulant (150 IU/ml, 1:9 v/v), and
centrifuged at 6500 RCF for 15 min to obtain plasma. Plasma
samples were stored at –20◦C until the day of the assay.
IL-1β and TNFα plasmatic concentrations were determined in
duplicate using commercially available ELISA kits according
to the procedures supplied by the manufacturer (PRODOTTI
GIANNI S.p.A., Milano, Italy) and the results expressed as pg/ml
of plasma.
Colonic 5-HT Levels
5-HT concentration was determined in the supernatant of colon
homogenates with a commercially available EIA kit (Abnova)
according to the manufacturer’s protocol. Samples were weighed,
homogenized for 1 min in 1 ml of ice-cold 0.01 M HCl
solution containing 1% ascorbic acid and centrifuged at 4000
RCF at 4◦C for 15 min. Enzymatic reaction products were
determined in duplicate spectrophotometrically at 450 nm, the
assay sensitivity being 5 ng/ml (Jenway, mod. 6300, Dunmow,
Essex, England). Results were normalized with colonic edema
values and expressed as µ/g dry weight tissue.
Colonic SP Levels
Substance P concentration was determined in the supernatant
of colon homogenates with a commercially available EIA kit
(Cayman Chemicals) following manufacturer’s protocol. Samples
were weighed, homogenized for 1 min in 1 ml of ice-cold PBS (pH
7.4) solution containing protease inhibitors cocktail (pepstatin,
aprotinin, and leupeptin 1 µg ml−1) and centrifuged at 6500
RCF at 4◦C for 15 min. Enzymatic reaction products were
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determined in duplicate by spectrophotometry at 405 nm, the
assay sensitivity being 8 pg/ml. Results were expressed as ng/g
dry weight tissue.
Plasmatic Nitrites Levels
Nitrates plus nitrites levels in plasma samples were determined
according to Guevara’s method for the determination of
nitrite/nitrate by Griess reaction (Guevara et al., 1998). 100
microliter of plasma were incubated with 10 µl of nitrate
reductase (500 mU/ml) and 10 µl of NADPH (860 µM) for 2 h at
37◦C, in the dark, to reduce nitrates to nitrites. After reduction,
240 µl of methanol/diethyl ether solution (3:1 v/v) were added
to each sample and incubated overnight to induce protein
denaturation and precipitation. The following day, samples were
centrifuged for 10 min at 12500 RCF at 4◦C, 100 µl of the
supernatant were mixed with 25 µl of HCl 6N and 25 µl of 37.5 M
sulphanilic acid and incubated for 10 min at room temperature.
Finally, 25 µl of 12.5 M 1-naftilendiammine were added to
each sample and incubated for 30 min at room temperature.
The absorbance of the samples were measured in duplicate by
spectrophotometry at 550 nm and expressed as µg/ml of plasma,
the assay sensitivity being 100 ng/ml.
Colonic Caspase-3 and HSP70 Levels
Samples of colon were homogenized for 1 min in 1 ml of
ice-cold PBS (pH 7.4) solution containing protease inhibitors
cocktail (pepstatin, aprotinin, and leupeptin 1 µg ml−1) and
centrifuged at 3000 RCF at 4◦C for 15 min. The supernatant
was collected, total protein concentration was quantified using
Pierce BCA protein assay kit (ThermoFisher Scientific Inc., MA,
USA) and an aliquot of the supernatant containing 100 mg
proteins/ml (for Caspase-3 assay) and 200 mg proteins/ml (for
HSP70 assay) were tested in commercially available ELISA kits
(PRODOTTI GIANNI S.p.A., Milano, Italy), according to the
manufacturer’s protocols. Each sample was assayed in duplicate
and the optical density of the final enzymatic reaction products
was determined at 450 nm. The sensitivity of the assays was
0.156 ng/ml (Caspase-3) and 200 pg/ml (HSP70). Results were
expressed as ng/mg protein (Caspase-3) or as pg/mg protein
(HSP70).
Intestinal Histology
Samples of colon harvested from normal animals and from colitic
mice administered with saline, Ketanserin 5 mg/kg and 8-OH-
DPAT 1 mg/kg were flushed with saline, immersion-fixed in 10%
neutral buffered formalin overnight, dehydrated and embedded
in paraffin. For each sample, at least five transverse 5-µm sections
were cut both in the proximal and in the distal colon, stained
with hematoxilin-eosin and examined in a light microscope
(Nikon Eclipse E800) by a person unaware of the treatment. To
assess histological injury in each section, the severity of mucosal
destruction (0, normal; 1, mild; 2, moderate; 3, severe) and
the extent of leukocytes infiltration in the lamina propria and
submucosa (0, absent; 1, mild; 2, pronounced) were graded and
the sum of scores was calculated (maximum score: 7) (modified
from Bischoff et al., 2009). Since histological injury produced by
TNBS instillation was localized almost exclusively in the distal
portion of the colon, the average value of histological score was
determined only from sections of distal colon, pooled with those
determined for the other animals of the same experimental group
and the mean value± SEM was calculated.
Statistical Analysis
All data were presented as means ± SEM. Comparison among
groups were made using analysis of variance (one-way ANOVA)
followed by Bonferroni’s post-test. Non-parametric Kruskal-
Wallis analysis followed by Dunn’s post-test was applied for
statistical comparison of DAI, MS, and cytokines levels. P < 0.05,
P < 0.01, and P < 0.001 showed, respectively, statistically
significant, highly significant, or extremely highly significant
differences. All analyses were performed using Prism 4 software
(GraphPad Software Inc. San Diego, CA, USA).
Drugs
WAY100135 (5-HT1A antagonist), GR125487 (5-HT4 anta-
gonist), and SB-269970 (5-HT7 antagonist) were purchased from
Tocris Bioscence (Bristol, UK). Ondansetron (5-HT3 antagonist)
was purchased from Glaxo Wellcome (Uxbridge, Middlesex, UK).
8-OH-DPAT (5-HT1A agonist), Ketanserin (5-HT2A antagonist),
TNBS, MPO and all the other chemicals of reagent grade were
purchased from Sigma–Aldrich Chemical Company (St. Louis,
MO, USA). Drugs were dissolved in saline solution the day of the
experiment.
RESULTS
TNBS Induced Severe Colitis in Mice
Intrarectal administration of the haptenating agent TNBS in
saline-treated mice induced a global worsening of health
conditions, expressed as DAI index, with respect to N animals:
progressive reduction of body weight and loss of stool consistency
were evident and reached their maximum at day 4, when animals
were sacrificed (P < 0.001 Dunn’s test, Figure 1A). Macroscopic
damage scores, based on the presence of adhesions, points of
stenosis, mucus, erythemas, and ulcers in colon specimens were
significantly increased after induction of TNBS colitis compared
with N animals, that had only sporadically and scarcely visible
rectal erythemas (P < 0.001 Dunn’s test, Figure 1B); colonic
length was markedly reduced (P < 0.001 Bonferroni’s test,
Figure 1C) and, conversely, thickness (P < 0.001 Bonferroni’s
test, Figure 1D) and edema (5.3 ± 0.1 C vs. 3.6 ± 0.3 N
group, P < 0.001 Bonferroni’s test) augmented following TNBS
administration.
Consistent with these alterations, the microscopic analysis
revealed diffuse epithelial degeneration and massive neutrophilic
infiltration of the distal colonic wall in TNBS-inoculated mice
(Figure 2B; histological score: 6.0 ± 1.0) with respect to normal
animals (Figure 2A; histological score: 0).
These local morphological changes were accompanied by
systemic inflammatory responses, represented by increased liver
edema (2.20 ± 0.02 vs. 1.84 ± 0.02 N group, P < 0.001
Bonferroni’s test), intense infiltration of leukocytes in the
colon as well as in lungs, witnessed by the increase in MPO
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FIGURE 1 | Effects of 5-HT receptor antagonists on TNBS-induced disease severity. DAI at day 4 (A), MS (B), colonic length (C), and colonic thickness
(D) assessed in normal mice (N) and in TNBS-treated mice administered with vehicle (C), WAY100135 5 mg/kg (W), Ketanserin 5 mg/kg (K), Ondansetron
10mg/kg (O), GR125487 10 mg/kg (G) and SB269970 10 mg/kg (S) (n = 6–12 data per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. N mice; #P < 0.05,
##P < 0.01 vs. C mice; one-way ANOVA followed by Bonferroni’s post-test. Kruskal–Wallis analysis followed by Dunn’s post-test was applied for statistical
comparison of DAI and MS.
activity (P < 0.001 vs. N Bonferroni’s test, Figure 3), and by
the remarkable up-regulation of pro- and anti-inflammatory
cytokines both in colonic tissues and in plasma of colitic mice
(Figure 4). In this condition of severe colonic inflammation,
tissue 5-HT content (P < 0.001 Bonferroni’s test) and plasmatic
nitrites (P < 0.05 Bonferroni’s test) were more than doubled in C
mice compared to N animals (Table 1).
5-HT2A Blocker Attenuated the Severity
of TNBS-Induced Colitis
Among the different 5-HT receptor antagonists tested, only
repeated administration of 5-HT2A antagonist Ketanserin
5 mg/kg slightly improved health conditions of colitic mice and
counteracted both colon shortening (P < 0.05) and thickening
(P < 0.01) produced by TNBS intrarectal instillation, even if
without reducing the MS (Figure 1) or the microscopic damage
(Figure 2C; histological score: 6.3± 0.7).
Blockade of 5-HT2A receptors significantly contrasted
the infiltration of the TNBS-inflamed intestine with
polymorphonuclear leukocytes (P < 0.05) and dampened
the increase in lung MPO activity exhibited by colitic mice
(Figure 3). The anti-inflammatory action of Ketanserin was
evident also when considering the levels of bowel and plasmatic
cytokines: indeed, the 5-HT2A blocker was able to globally revert
the increase in inflammatory cytokines evoked in TNBS colitis
both in colon and in plasma (Figure 4), where TNFα and IL-1β
concentrations were reduced, respectively, up to 5 (P < 0.05) and
2.5 times compared to C animals.
In order to investigate the possible mechanism underlying
the protective effects displayed by Ketanserin, colonic levels of
caspase-3, apoptotic marker, and of HSP70, a stress-inducible
protein with cytoprotective properties, were determined in N,
C, and Ketanserin-treated mice. As expected, TNBS enema
produced a remarkable increase of caspase-3 levels and a highly
significant reduction of HSP70: Ketanserin was able to counteract
caspase-3 rise (P < 0.05 vs. C) but it did not affect HSP70 decrease
(Figure 5).
5-HT1A Blocker Worsened Neutrophil
Infiltration in TNBS-Induced Colitis
Subcutaneous administration of 5-HT1A antagonist WAY100135
10 mg/kg to TNBS-treated mice did not modify significantly
the progression of the pathology nor the macroscopic damage
score, slightly increasing only colon wall thickness in comparison
with C mice (Figure 1). However, both intestinal and lung
tissues excised from animals administered with 5-HT1A blocker
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FIGURE 2 | Histology. Representative hematoxylin-eosin stained sections of colonic specimens harvested from normal mice (A) and from TNBS-treated mice
administered with vehicle (B), Ketanserin 5 mg/kg (C) or 8-OH-DPAT 1 mg/kg (D). TNBS colonic instillation caused epithelial degeneration, neutrophilic
infiltration, and submucosal edema (indicated by arrows) in vehicle-treated animals (B), not overtly modified either by Ketanserin (C) or 8-OH-DPAT (D)
treatment.
FIGURE 3 | Effects of 5-HT receptor antagonists on TNBS-induced neutrophil infiltration in colon and lung. MPO activity in colonic (A) and lung (B)
tissues excised from normal mice (N) and from TNBS-treated mice administered with vehicle (C), WAY100135 5mg/kg (W), Ketanserin 5mg/kg (K), Ondansetron
10mg/kg (O), GR125487 10mg/kg (G), and SB269970 10mg/kg (S) (n = 6–12 data per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. N mice; #P < 0.05,
##P < 0.01, ###P < 0.001 vs. C mice; one-way ANOVA followed by Bonferroni’s post-test.
exhibited a conspicuous up-regulation of MPO activity, an index
of neutrophil recruitment, with respect to vehicle-treated mice:
in fact, treatment with WAY100135 nearly doubled MPO levels
from 96.7 ± 7.3 U/g in the gut and 116.6 ± 6.9 U/g in lungs to,
respectively, 150.8 ± 20.3 U/g and 182.6 ± 19.7 U/g (Figure 3).
5-HT1A antagonist did not overtly modify the increased amount
either of local or systemic inflammatory cytokines produced by
TNBS (Figure 4).
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FIGURE 4 | Effects of 5-HT receptor antagonists on cytokines levels. Colonic concentrations of TNFα (A), IL-1β (B), IFNγ (C), and IL-10 (D) and plasmatic
levels of TNFα (E) and IL-1β (F) in normal mice (N) and in TNBS-treated mice administered with vehicle (C), WAY100135 5 mg/kg (W), Ketanserin 5 mg/kg (K),
Ondansetron 10 mg/kg (O), GR125487 10 mg/kg (G) and SB269970 10 mg/kg (S) (n = 6–12 data per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. N mice;
#P < 0.05 vs. C mice; Kruskal–Wallis analysis followed by Dunn’s post-test.
TABLE 1 | 5-HT, nitrites, and SP levels in plasma and colonic samples excised from normal mice (N) and from colitic mice administered with saline (C),
WAY100135 5 mg/kg (W), and 8-OH-DPAT 1 mg/kg (OH) (n = 6–12 data per group).
N C W OH
Colonic 5-HT (g/g) 6.5 ± 0.8 16.1 ± 1.1a 14.7 ± 1.4b 11.2 ± 2.0c
Plasmatic nitrites (g/ml) 0.5 ± 0.1 1.1 ± 0.1d 1.6 ± 0.2a,c 1.3 ± 0.1b
Colonic SP (ng/g) 99.4 ± 13.5 260.9 ± 52.4 235.6 ± 41.9 215.1 ± 25.0
Data are mean ± SEM. aP < 0.001; bP < 0.01 vs. N mice; cP < 0.05 vs. C mice; dP < 0.05 vs. N mice – one-way ANOVA followed by Bonferroni’s post-test.
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FIGURE 5 | Effect of Ketanserin on colonic caspase-3 and HSP70 levels. Colonic concentrations of caspase-3 (A) and HSP70 (B) in normal mice (N) and in
TNBS-treated mice administered with vehicle (C) or Ketanserin 5 mg/kg (K) (n = 6–12 data per group). ∗P < 0.05, ∗∗P < 0.01 vs. N mice; #P < 0.05 vs. C mice;
one-way ANOVA followed by Bonferroni’s post-test.
FIGURE 6 | Effects of 5-HT1A ligands on disease progression. Colitis
severity, expressed as DAI, assessed on all four days following TNBS i.r.
instillation in normal mice (black circles) and in mice administered with vehicle
(black squares), WAY100135 5 mg/kg (black triangles) and 8-OH-DPAT
1mg/kg (white triangles) (n = 6–12 data per group). ∗∗P < 0.01, ∗∗∗P < 0.001
vs. N mice; #P < 0.05, ###P < 0.001 vs. C mice; Kruskal–Wallis analysis
followed by Dunn’s post-test.
5-HT1A Agonist Weakly Mitigated the
Severity of TNBS-Induced Colitis
Administration of 5-HT1A agonist 8-OH-DPAT 1 mg/kg to
TNBS-treated mice remarkably improved their health conditions,
DAI scoring being significantly lower than that of vehicle-
treated mice every day of the observation period (Figure 6).
Moreover, exogenous stimulation of 5-HT1A receptors attenuated
the thickening (55.0± 2.4 mg/cm vs 68.7± 3.4 C mice, P < 0.01)
and the increase in colonic edema (4.8± 0.2 vs. 5.4± 0.1 C mice,
P < 0.05) observed in segments excised from control mice, but
did not reduce the mucosal damage, macroscopically or histo-
pathologically detected (Figure 2D; histological score: 6.0± 1.0),
nor the local and systemic leukocyte infiltration (data not shown)
or cytokines release (Figure 7).
FIGURE 7 | Effects of 8-OH-DPAT on cytokines levels. Colonic
concentrations (pg/mg protein) of TNFα, IL-1β, IFNγ, and IL-10 and plasmatic
levels (pg/ml) of TNFα and IL-1β in normal mice (white bars) and in
TNBS-treated mice administered with vehicle (black bars) and 8-OH-DPAT
1mg/kg (gray bars) (n = 6–12 data per group). ∗P < 0.05, ∗∗P < 0.01 vs. N
mice; Kruskal–Wallis analysis followed by Dunn’s post-test.
Interestingly, bowel 5-HT content was significantly decreased
following 8-OH-DPAT treatment with respect to vehicle-treated
colitic animals (P < 0.05, Table 1). Along with 5-HT, we
investigated the role of 5-HT1A receptors in affecting the
release also of other mediators typically involved in intestinal
inflammation. Accordingly, the levels of plasmatic nitrites and
of colonic SP were assessed following 5-HT1A stimulation
and blockade in TNBS-treated mice: while 5-HT1A antagonist
significantly augmented the levels of nitrites when compared with
N (P < 0.001) or C mice (P < 0.05), 8-OH-DPAT did not modify
either nitrites or SP levels (Table 1).
Blockade of 5-HT3, 5-HT4, and 5-HT7
Receptors Did Not Remarkably Affect
the Severity of TNBS-Induced Colitis
The administration of 5-HT4 antagonist GR125487 10 mg/kg
reduced DAI index at day 4 and colon thickness (P < 0.05)
with respect to C mice (Figure 1), but had no clear effect on
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the other local and systemic inflammatory responses. Blockade of
5-HT3 receptors by Ondansetron 10 mg/kg and 5-HT7 receptors
by SB269970 10 mg/kg provoked an increase in mortality rate
of, respectively, 40 and 25% (data not shown), preventing
experiments at higher dosages. Neither of the treatments applied
were able to significantly aggravate or improve any of the clinical,
macroscopic and biochemical parameters examined.
DISCUSSION
The results collected in the present study indicate that:
• TNBS intrarectal instillation in mice produced a strong local
and systemic inflammatory response, associated with increased
colonic levels of 5-HT;
• improved global health conditions, reduced morphological
colonic changes and down-regulation of neutrophil
recruitment and of inflammatory cytokines levels were
produced by antagonism of 5-HT2A receptors;
• blockade of 5-HT1A receptors worsened neutrophil
recruitment while, conversely, exogenous stimulation of
the same receptor subtype delayed and mitigated the severity
of TNBS-induced colitis, contrasting the increase in colonic
5-HT content;
• blockade of 5-HT3, 5-HT4, and 5-HT7 receptors did not
remarkably affect the progression and outcome of the
pathology or only slightly improved it.
The central role of 5-HT in modulating GI peristaltic and
secretory reflexes has been known for a long time (Tonini,
2005); more recently, the influence of 5-HT also on innate
and adaptive immune responses and on enteric inflammation
has been emerging. The clinical and experimental studies
currently available indicate a pro-inflammatory contribution of
the monoamine to the pathogenesis of intestinal disorders like
IBD (El-Salhy et al., 1997; Bischoff et al., 2009; Ghia et al.,
2009; Margolis et al., 2014), although the mechanisms underlying
and the receptor subtypes mediating this effect have yet to be
identified.
In order to shed some light on the role played in intestinal
inflammation by the 5-HT receptor subtypes most abundantly
expressed in the GI tract, we chose a conventional chemical
model of experimental colitis mainly driven by a Th1-mediated
immune response, although well aware that no single model can
perfectly mimic human IBD complexity (Kiesler et al., 2015).
As expected, intrarectal TNBS challenge in mice produced a
severe state of illness accompanied by colonic and systemic
inflammatory responses and, consistent with the literature, by
a higher 5-HT tissue amount (Oshima et al., 1999; Linden
et al., 2003). Therefore, our findings apparently represent a new
clue in favor of the pro-inflammatory role of the monoamine.
However, when the overall results of the present investigation
were examined, a more complex picture emerged, actually
mirroring a multifaceted role of endogenous 5-HT in intestinal
inflammation.
Repeated treatment of TNBS-challenged mice with different
5-HT receptor antagonists produced heterogeneous results,
showing that endogenous 5-HT could provide simultaneously a
deleterious and, alternatively, a beneficial contribution. Among
the various 5-HT blockers applied, only 5-HT2A antagonist
Ketanserin protected animals against TNBS-induced colitis,
attenuating the gravity of the local alterations and of the systemic
inflammatory state. The ability of Ketanserin to markedly
prevent both the colon shortening and the development of
an inflammatory infiltrate, consisting presumably mainly of
polymorphonuclear leukocytes, seems to indicate that, once
released by EC cells following TNBS challenge (Bischoff et al.,
2009; Margolis et al., 2014), endogenous 5-HT may participate
in the up-regulation of colonic and plasmatic inflammatory
cytokines and, consequently, to the recruitment of activated
phagocytes in the bowel through the stimulation of 5-HT2A
receptors. 5-HT2 receptors have been described to influence
several immune responses, by promoting the chemotaxis of
immature dendritic cells (Muller et al., 2009) and eosinophils
(Boehme et al., 2004) and activating CD4+ and CD8+ T
lymphocytes (Inoue et al., 2011); conversely, blockade of the
same receptor subtype by Ketanserin was able to counteract the
up-regulation of inflammatory cytokines in a model of systemic
inflammation (Sugino et al., 2009). Our present findings are
in line with these observations and point toward the beneficial
immunomodulatory effects of selective 5-HT2A pharmacological
blockade.
Besides the reduction in pro-inflammatory cytokines levels,
the amelioration induced by Ketanserin on TNBS colitis may
depend also on its anti-apoptotic effects on colonic tissues.
Indeed, intestinal epithelial cells apoptosis is increased in the
mucosa of IBD patients and in experimental colitis, although it is
still unclear whether excessive cell death is the origin or simply
a consequence of the inflammatory environment promoted in
IBD (Günther et al., 2013); as a result, anti-apoptotic effects are
often considered decisive to the protection afforded by a number
of different therapeutic strategies in experimental colitis (see
for instance Crespo et al., 2012; Arumugam et al., 2015; Yang
et al., 2015). Interestingly, beneficial anti-apoptotic effects were
demonstrated also by 5-HT2 antagonists in myocardial injury
(Rajesh et al., 2006; Bharti et al., 2015). Altogether, our data
lend support to a potential application of 5-HT2A antagonists as
supplemental strategy, combining anti-inflammatory and anti-
apoptotic actions, for the treatment of intestinal inflammatory
disorders.
Blockade of 5-HT4 receptors by GR125487 only partially
overlapped the protective action of Ketanserin, weakly improving
clinical conditions and attenuating colonic thickening: it is likely
that the localization of 5-HT4 receptors on dendritic cells and
their activating effects on immune cells functions (Idzko et al.,
2004) could come into play in this regard.
If, in our experimental conditions, endogenous activation of
5-HT2A and 5-HT4 receptors seems to contribute to the TNBS-
induced damage, simultaneous stimulation of 5-HT1A sites
apparently contrasts the neutrophil recruitment triggered both
locally and systemically by TNBS challenge, as demonstrated by
the enhancing effect shown by 5-HT1A antagonist WAY100135
on the strong leukocytes migration in colon and lungs induced
by the instillation of the haptenating agent. Consistent with these
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findings is the protective action displayed by 5-HT1A agonist
8-OH-DPAT, which improved the general health conditions
of colitic mice and attenuated the wall structural alterations
elicited by TNBS application. This advantageous effect exerted by
stimulation of 5-HT1A sites is not easily interpreted by taking into
account their immunomodulatory actions documented in vitro,
such as the inhibition of T cell proliferation and activity produced
by 5-HT1A antagonism (Aune et al., 1994). On the other hand,
it is well known that 5-HT1A receptors are present also on
neural elements in the gut, where they pre-synaptically inhibit
the release of Ach and of non-cholinergic neurotransmitters
(LePard et al., 2004). Following this line of evidence, we tested
the hypothesis that activation of 5-HT1A receptors could interfere
with the release of SP, a neuropeptide documented to be
up-regulated and directly involved in IBD-induced intestinal
inflammation (Gross and Pothoulakis, 2007). On the basis of the
findings here collected we could rule out this possible mechanism
of action, since neither 5-HT1A agonist nor antagonist produced
significant changes in the levels of colonic SP.
As regards the effects of 5-HT1A receptor modulation on
NO availability, several investigations documented a greatly
increased production of this labile mediator in IBD and in
experimental colitis and highlighted its pro-inflammatory and
detrimental role or vice-versa its homeostatic and protective
action in the pathogenesis of intestinal injury (Perner and
Rask-Madsen, 1999; Kolios et al., 2004). In our conditions,
the increased levels of plasmatic nitrites, stable metabolites of
NO, detected in TNBS-colitis seem to support the potential
harmful effects of this mediator; blockade of 5-HT1A receptors
further augmented the amount of NO, likely contributing to
the negative outcome of WAY100135 treatment. On the whole,
we can speculate that endogenous 5-HT may participate via 5-
HT1A receptors in limiting the massive neutrophils recruitment
triggered in TNBS-colitis possibly by restraining NO over-
production.
Interestingly, 5-HT1A receptors have been localized also on EC
cells (Kirchgessner et al., 1996) from which 5-HT can modulate
its own release (Schworer and Ramadori, 1998). The efficacy
exhibited by 8-OH-DPAT in reducing 5-HT colonic content
could therefore reflect the role played by 5-HT1A receptors
in regulating 5-HT availability from EC cells in the inflamed
gut. It is tempting to hypothesize that the beneficial effect
provided by 5-HT1A agonist in this model of TNBS-induced
colitis might depend on the reduced intestinal 5-HT content,
further highlighting the pro-inflammatory and deleterious role of
the monoamine.
Finally and unexpectedly, neither blockade of 5-HT3 nor that
of 5-HT7 receptors was able to significantly modify the disease
progression and the intensity of the inflammatory response
elicited by TNBS challenge. In fact, our results apparently
contrast with recent investigations documenting the protection
provided by 5-HT3 antagonists in TNBS-induced colitis in rats
(Motavallian et al., 2013) and in 5-fluorouracil-induced intestinal
mucositis in mice (Yasuda et al., 2013) and the controversial role,
either protective or deleterious, described for 5-HT7 receptors
in DSS-induced colitis (Kim et al., 2013; Guseva et al., 2014).
However, differences between species, models of colitis and
doses of SB-269970 administered could account for the observed
discrepancies.
CONCLUSION
Our findings shed new light on the double-faced role of 5-HT
in intestinal delayed inflammation: the prevailing deleterious
contribution mediated by 5-HT2A and 5-HT4 receptors
activation co-exists and is partially counteracted by 5-HT1A
stimulation, suggesting that agents targeting serotoninergic
system could be beneficial as an additional therapeutic strategy
in IBD only by carefully dissecting the monoamine antithetical
effects.
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